Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (13973)	1/30/1998 4:29:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

FUGAZI. LGND's screening allows them to screen for agonists as well as antagonists. Thus in the area of retinoids and rexinoids, the compounds in trials are agonists (they act like Vitamin A metabolites). However, AGN will soon be entering an anti-retinoid (antagonist) into trails to counter-act some of the side effects of agonist (like Retin-A, Renova, and Accutane). Similarly, AHP has licensed progesterone agonists and antagonists from LGND (see home.att.net - Expanded program for Progestins). Thus, LGND could screen for both types of compounds, agonist to grow hair and antagonists to remove hair. For more background, see the "Cosmeceuticals" section of Genetic Engineering News under Background at home.att.net .